At the Veeva Clinical Oversight Forum, we spoke with Pinar Bénet, Senior Director of GTM Strategy and Clinical Lead at Veeva Systems, about how R3 is reshaping the future of sponsor oversight.
Bénet emphasized that timely access to operational data is now foundational to meaningful oversight, noting that sponsors cannot distinguish noise from true signals without it. She shared that outsourcing models are evolving as sponsors increasingly bring data management in-house to maintain control and standardization.
Discussing organizational readiness, Bénet highlighted that legacy waterfall thinking remains one of the greatest barriers to proactive quality. She noted that agile oversight requires agile technology and cross-functional collaboration, which legacy systems were never designed to support.
She also introduced the idea of proportionate oversight, explaining how R3 compels sponsors to tailor quality actions based on study-specific risks rather than relying on rigid SOP hierarchies. This shift, she added, prevents unnecessary bureaucracy while strengthening accountability.
Bénet urged the industry to move toward clearer standards and shared methodologies for continuous oversight. “Sponsors understand the words, but what’s missing are concrete, repeatable examples of how to execute,” she said.
This content is sponsored by Veeva Systems.
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
